China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
Rhea-AI Summary
China Pharma Holdings, Inc. (NYSE American: CPHI) has announced plans to launch its Dry Eye Disease Therapeutic Device in China by Q1 2025. The device, developed by its subsidiary Hainan Helpson Medical and Biotechnology Co., , is a patented medical treatment for dry eye disease. With 400 million dry eye disease patients in China, the market is projected to reach $579.51 million by 2030, growing at a CAGR of 6.04% from 2023-2030.
The device uses ophthalmic oxygen-enriched atomization technology to spray tiny oxygen-rich droplets into the eyes, improving moisture, oxygen supply, and tear fluid quality. This physical therapy approach aims to avoid drug-related side effects while providing more direct and comfortable treatment.
Positive
- Launch of patented Dry Eye Disease Therapeutic Device expected in Q1 2025
- Large market potential with 400 million dry eye disease patients in China
- Chinese dry eye disease market projected to reach $579.51 million by 2030
- Innovative technology using oxygen-enriched atomization for treatment
Negative
- None.
News Market Reaction
On the day this news was published, CPHI gained 0.30%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- It is a medical treatment device for dry eye disease under patent protection;
- The Company, through Helpson, acquired the technology at the end of 2022 and has subsequently carried out the corresponding commercialization, as well as the registration and application process of the product;
- It has completed production commissioning and third-party testing by now.
In
Treatments for dry eye-related indications include two forms of secretagogues, oral and topical, which are widely recommended for first-line and second-line treatments. A major factor driving the segment's growth includes the awareness campaigns regarding dry eye diseases by vision science and optometry. Our device is embedded with an ophthalmic oxygen enriched atomization therapeutic instrument.
Using such technology, our device can spray tiny oxygen-rich droplets evenly into patient's eyes, thereby increasing the moisture and oxygen supply of the eye surface and improving the quality and stability of the tear fluid. This type of physical therapy avoids the side effects that may be brought about by drugs, and can also effect more directly on the eyes, improving the effectiveness and comfort of the treatment.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty pharmaceutical company that develops, manufactures, and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.
View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc--expects-to-launch-its-dry-eye-disease-therapeutic-device-in-the-first-quarter-of-2025-302225097.html
SOURCE China Pharma Holdings, Inc.
FAQ
When will China Pharma Holdings (CPHI) launch its Dry Eye Disease Therapeutic Device?
What is the market size for dry eye disease in China?
How does China Pharma's (CPHI) Dry Eye Disease Therapeutic Device work?
What is the prevalence of dry eye disease in China?
